Efficacy and safety of polymyxins for the treatment of Acinectobacter baumannii infection: A systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Liu, Qianqian ^a   Li, Wenzhang ^b   Feng, Yulin ^a   Tao, Chuanmin ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; COLISTIN; COTRIMOXAZOLE; DORIPENEM; DOXYCYCLINE; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; POLYMYXIN;

ACINETOBACTER INFECTION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LENGTH OF STAY; META ANALYSIS; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; DRUG EFFECTS; PATIENT SAFETY; PHYSIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; HUMANS; LENGTH OF STAY; PATIENT SAFETY; POLYMYXINS;

EID: 84902585467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098091     Document Type: Review

References (54)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, et al. (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317. (Pubitemid 39050477)
2. Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, et al. (2005) Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997-2002. J Hosp Infect 60: 256-260. (Pubitemid 40790466)
3. Nordmann P (2004) [Acinetobacter baumannii, the nosocomial pathogen par excellence]. Pathol Biol (Paris) 52: 301-303.
4. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, et al. (2007) Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 13: 97-103. (Pubitemid 46057843)
5. Infectious Diseases Society of A (2010) The 10x'20 Initiative: pursuing a globalcommitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50: 1081-1083.
6. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281.
7. Benedict RG, Langlykke AF (1947) Antibiotic activity of Bacillus polymyxa. J Bacteriol 54: 24.
8. Stansly PG, Shepherd RG, White HJ (1947) Polymyxin: a new chemotherapeutic agent. Bull Johns Hopkins Hosp 81: 43-54.
9. Falagas ME, Rafailidis PI (2008) Re-emergence of colistin in today's world of multidrug-resistant organisms: personal perspectives. Expert Opin Investig Drugs 17: 973-981.
10. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G (2006) Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 25: 596-599. (Pubitemid 44379694)
11. Ruiz J, Núñez ML, Pérez J, Simarro E, Martínez-Campos L, et al. (1999) Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. Eur J Clin Microbiol Infect Dis 18: 292-295. (Pubitemid 29527977)
12. Sands M, McCarter Y, Sanchez W (2007) Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E-test methodology. Eur J Clin Microbiol Infect Dis 26: 521-522. (Pubitemid 47025046)
13. Tascini C, Menichetti F, Bozza S, Del Favero A, Bistoni F (1998) Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 42: 270-271. (Pubitemid 28393603)
14. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, et al. (2007) In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 60: 317-322. (Pubitemid 47243880)
15. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, et al. (2006) In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 27: 224-228. (Pubitemid 43246952)
16. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25: 11-25. (Pubitemid 40023341)
17. Savage PB (2001) Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria. Ann Med 33: 167-171.
18. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339: b2700.
19. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, et al. (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36: 1111-1118. (Pubitemid 36549630)
20. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56: 432-436.
21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12. (Pubitemid 26120810)
22. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. (2012) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinicalepidemiology/ oxford.asp. Accessed 2013 Nov 10.
23. Chan JD, Graves JA, Dellit TH (2010) Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 25: 343-348.
24. Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, et al. (2011) Safety in treatment of ventilator-associated pneumonia due to extensive drugresistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report. Pediatric pulmonology 46: 60-66.
25. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, et al. (2012) Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 7: e52349.
26. Kang CH, Tsai CM, Wu TH, Wu HY, Chung MY, et al. (2013) Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity. Pediatr Pulmonol.
27. Gounden R, Bamford C, van Zyl-Smit R, Cohen K, Maartens G (2009) Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 9: 26.
28. Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM (2006) Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 40: 1939-1945. (Pubitemid 44747462)
29. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, et al. (2013) Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenemresistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141: 1214-1222.
30. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, et al. (2013) Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57: 349-358.
31. Kalin G, Alp E, Akin A, Coskun R, Doganay M (2013) Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection.
32. Jang HJ, Kim MN, Lee K, Hong SB, Lim CM, et al. (2009) The Comparative Efficacy of Colistin Monotherapy and Combination Therapy Based on in vitro Antimicrobial Synergy in Ventilator-associated Pneumonia Caused by Multidrug Resistant Acinetobacter baumannii. Tuberculosis and Respiratory Diseases 67: 212-220.
33. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, et al. (1994) Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344: 1329-1332. (Pubitemid 24343197)
34. El Shafie SS, Alishaq M, Leni Garcia M (2004) Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in trauma intensive care unit. J Hosp Infect 56: 101-105. (Pubitemid 38153058)
35. Afzal-Shah M, Livermore DM (1998) Worldwide emergence of carbapenemresistant Acinetobacter spp. J Antimicrob Chemother 41: 576-577. (Pubitemid 28230316)
36. Garnacho-Montero J, Ortiz-Leyba C, Fernandez-Hinojosa E, Aldabo-Pallas T, Cayuela A, et al. (2005) Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 31: 649-655. (Pubitemid 40684982)
37. Peleg AY, Seifert H, Paterson DL (2008) Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21: 538-582.
38. Jain R, Danziger LH (2004) Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38: 1449-1459. (Pubitemid 39100202)
39. Chu H, Zhao L, Wang M, Liu Y, Gui T, et al. (2013) Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis 17: 389-394.
40. Tasina E, Haidich AB, Kokkali S, Arvanitidou M (2011) Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 11: 834-844.
41. Lee YT, Tsao SM, Hsueh PR (2013) Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 32: 1211-1220.
42. Linden PK, Paterson DL (2006) Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43 Suppl 2: S89-94. (Pubitemid 44267146)
43. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, et al. (2006) Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28: 366e9.
44. Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40: 1333-1341. (Pubitemid 40570245)
45. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, et al. (1970) Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 72: 857-868.
46. Baines RD Jr, Rifkind D (1964) Intravenous Administration Of Sodium Colistimethate. JAMA 190: 278-281.
47. Price DJE, Graham DI (1970) Effects of large doses of colistin sulfomethate on renal function. Br Med J 4(5734): 525-527.
48. Pintado V, San Miguel LG, Grill F, Mejia B, Cobo J, et al. (2008) Intravenous colistin sulphomethate sodium for therapy of infections due to multidrugresistant gram-negative bacteria. J Infect 56: 185-190.
49. Reina R, Estenssoro E, Saenz G, Canales HS, Gonzalvo R, et al. (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31: 1058-1065. (Pubitemid 41125336)
50. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, et al. (2007) Safety and efficacy of colistin compared with imipenem in the treatment of ventilatorassociated pneumonia: a matched case-control study. Intensive Care Med 33: 1162-1167. (Pubitemid 47036903)
51. Pournaras S, Ikonomidis A, Markogiannakis A, Maniatis AN, Tsakris A (2005) Heteroresistance to carbapenems in Acinetobacter baumannii. J Antimicrob Chemother. 55: 1055-1056.
52. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, et al. (2006) Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50: 2946-2950. (Pubitemid 44396396)
53. Hawley JS, Murray CK, Jorgensen JH (2007) Development of colistindependent Acinetobacter baumanni-calcoaceticus complex. Antimicrob Agents Chemother 51: 4529-4530. (Pubitemid 350209922)
54. Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, et al. (2004) In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 53: 393-395.